Abstracts tagged "Anti-TNF therapy and rheumatoid arthritis (RA)"

Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting
US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Ting-Chun Yeh¹, Yolaine Jeune-Smith ¹, Eli Phillips ¹, Ajeet Gajra ¹ and Bruce Feinberg ¹, ¹Cardinal Health Specialty Solutions, Dublin, OH
Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…
Abstract Number: 1450 • 2017 ACR/ARHP Annual Meeting
Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients
Patricia Bogas¹, Chamaida Plasencia-Rodriguez¹, Alejandro Balsa¹, Dora Pascual-Salcedo², Gema Bonilla¹, Enrique Moral Coro¹, Carolina Tornero¹, Laura Nuño¹, Diana Peiteado³, Ana Martínez⁴ and Borja Hernández¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Immuno-Rheumatology research group, La Paz University Hospital, MADRID, Spain
Background/Purpose: There is currently no consensus on selecting a therapeutic target in patients (pts) non-responsive to their first TNF inhibitors (TNFi). The development of anti-drug…
Abstract Number: 2477 • 2017 ACR/ARHP Annual Meeting
Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA®
Denis Choquette¹, Louis Bessette², L Coupal³ and Kirsten Garces⁴, ¹University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, Canada, ²Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: Between 2000 and 2006, the only other treatment option for patients with rheumatoid arthritis (RA) first exposed to an anti-TNF agent was another anti-TNF…
Abstract Number: 2478 • 2017 ACR/ARHP Annual Meeting
Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®
Denis Choquette¹, Louis Bessette², Louis Coupal³ and Kirsten Garces⁴, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: Anti-TNFs have been used to treat RA since 2000. Since the availability of new agents with different mechanisms of action around 2007, the pattern…
Abstract Number: 2487 • 2017 ACR/ARHP Annual Meeting
Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF
Patricia Bogas¹, Chamaida Plasencia-Rodriguez¹, Alejandro Balsa¹, Victoria Navarro-Compán², Gema Bonilla¹, Enrique Moral Coro¹, Carolina Tornero¹, Laura Nuño¹ and Diana Peiteado³, ¹Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: There are many biological therapies for Rheumatoid Arthritis (RA) with different mechanisms of action and good efficacy rate; however, up to 40% of patients…
Abstract Number: 2488 • 2017 ACR/ARHP Annual Meeting
Golimumab Retention Rate in Patients with Rheumatoid Arthritis. Predictors of Long-Term Retention
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Julia Martínez-Barrio⁴, Juan Gabriel Ovalles-Bonilla⁵, Juan Carlos Nieto², Iustina Janta², Larissa Valor³, Francisco Javier López Longo⁶ and Indalecio Monteagudo², ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in rheumatoid arthritis (RA) has been widely documented. The aim of this study was to analize the long-term…
Abstract Number: 533 • 2016 ACR/ARHP Annual Meeting
What Proportion of Patients Fail to Achieve CDAI and SDAI Remission Based on Physician Global Assessment? an Analysis from the Prospective, Observational Registry
Michael Starr¹, Boulos Haraoui², Denis Choquette³, Louis Bessette⁴, Andrew Chow⁵, Philip Baer⁶, Suneil Kapur⁷, John Kelsall⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Francois Nantel¹², Allen J Lehman¹³, Brendan Osborne¹⁴, Karina Maslova¹³ and Cathy Tkaczyk¹⁴, ¹Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Credit Valley Rheumatology, Mississauga, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Balfour Medical Clinic, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Physician’s Global Assessment of Disease Activity (MDGA) is a measure that is frequently incorporated in disease activity indices which reflects the physician’s perception of…
Abstract Number: 612 • 2016 ACR/ARHP Annual Meeting
Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial
Johanna Sigaux¹, Florian Bailly^2,3, Frédérique Gandjbakhch^1,3, Violaine Foltz^1,3, Florence Tubach^4,5, Laure Gossec^1,6 and Bruno Fautrel^1,7, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²rheumatology, Pitié Salpêtrière Hospital, paris, France, ³Sorbonne Universités, UPMC Univ Paris 06, Paris, France, Paris, France, ⁴Aix-Marseille University, Marseille, France, ⁵Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 7501875013, Paris, France ;, Paris, France, ⁶Sorbonne Universités, UPMC University Paris 06, Paris, France, Paris, France, ⁷GRC08, Sorbonne Universités, UPMC Univ Paris 06, Paris, France, Paris, France
Background/Purpose: Tapering of TNF blockers (TNFb) in rheumatoid arthritis (RA) patients in sustained remission is feasible in short-term randomized controlled trials (RCT). Less data are…
Abstract Number: 625 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis
John Tesser¹, Shelly Kafka², Raphael J. DeHoratius³, Stephen Xu⁴, Kehzen L. Tang⁴, Elizabeth C. Hsia⁵ and Anthony Turkiewicz⁶, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Rheumatology Associates, Birmingham, AL
Background/Purpose: There is a paucity of data on the use of anti-TNF therapy in patients >65 years. In this sub-analysis of GO-FURTHER, we compare the…
Abstract Number: 1043 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28
Atul A. Deodhar¹, John D. Reveille², Diane D. Harrison³, Lilianne Kim⁴, Kim Hung Lo⁴ and Elizabeth C. Hsia^5,6, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Janssen Research & Development, LLC., Horsham, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the…
Abstract Number: 1453 • 2016 ACR/ARHP Annual Meeting
Treatment of BAFF Transgenic Mice with Anti-TNF: Monoclonals Are Associated with a Higher Risk of Lymphoma Than Etanercept
Gaetane Nocturne^1,2, Bineta Ly³, Saida Boudaoud⁴, raphaèle seror^5,6, Carole Nicco⁷, Christiane Chereau⁷, Niloufar Kavian^7,8, Frederic Batteux^7,8, Fabienne Mackay⁹, Fabien Vincent⁹, Thierry Lazure¹⁰, Sophie Ferlicot¹⁰, Lev Stimmer¹¹, Roman Krzysiek¹⁰, Salima Hacein-Bey¹⁰ and Xavier Mariette^12,13, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁶INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ⁷Institut Cochin, Paris, France, ⁸Immunology, APHP Hopital Cochin, Paris, France, ⁹Monash university, Melbourne, Australia, ¹⁰APHP Hopitaux universitaires Paris sud, Le Kremlin Bicetre, France, ¹¹CEA - MIRCen, Fontenay aux Roses, France, ¹²Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ¹³INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) have an increased risk of lymphoma and disease activity is the main risk factor. The impact of treatment,…
Abstract Number: 2493 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
Lorie A. Ellis¹, Raphael J. DeHoratius², Shelly Kafka³, Helen Varker⁴, Matthew Brouillette⁴ and Elisabetta Malangone-Monaco⁴, ¹Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Truven Health Analytics, Bethesda, MD
Background/Purpose: Infliximab (IFX) and golimumab (GLM-IV) for intravenous use are anti-TNF agents indicated for rheumatoid arthritis (RA) and differ in weight-based dose, induction schedule, and…
Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting
In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis
Dao Xuan Nguyen, Centre of Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…
Abstract Number: 106 • 2015 ACR/ARHP Annual Meeting
Does the Timing of Phenotype Assessment Influence Association Results in Pharmacogenetics Studies of Anti-TNF Response in Rheumatoid Arthritis?
Kyoko Honne¹, Nicholas Jewell², Takeo Sakurai³, Masahiro Iwamoto⁴, Seiji Minota⁴ and Damini Jawaheer⁵, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²UC Berkeley, Berkeley, CA, ³Inoue Hospital, Takasaki, Japan, ⁴Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁵Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Pharmacogenetics studies of anti-tumor necrosis factor (TNF) response among patients with rheumatoid arthritis (RA) have routinely used assessment of response at a single time-point,…
Abstract Number: 2780 • 2015 ACR/ARHP Annual Meeting
Relationship Between Immunogenicity, Hypersensitivity Reactions and Skin Tests Against Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Firas Doghanji¹, Sebnem Ataman², Ali Erhan Ozdemirel², Recep Bülent Seckin¹, Ayse Peyman Yalcin¹ and Sevim Bavbek³, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, ³Immunology and Allergy, Ankara University Faculty of Medicine, Ankara, Turkey
Relationship between immunogenicity, hypersensitivity reactions and skin tests against Infliximab, Etanercept and Adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis Background/Purpose: Anti-TNF drugs can…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.